Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 81

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 81
---
 these exemptions until we are no longer an “emerging growth company.” We will remain an emerging growth company until the
earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the date of our first sale of equity securities
pursuant to an effective registration statement under the Securities Act, (b) in which we have total annual gross revenue of at least
$1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary Shares that
is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion
in non-convertible debt during the prior three-year period.

<div align='center'>49</div>

We cannot predict if investors
will find our ADSs or our Ordinary Shares less attractive because we may rely on these exemptions. If some investors find our ADSs or
our Ordinary Shares less attractive as a result, there may be a less active trading market for our ADSs or our Ordinary Shares, and our
market prices may be more volatile and may decline.

As a “foreign private issuer” we are permitted to and follow certain home country corporate governance practices instead of otherwise applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.

Our status as a foreign
private issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of the NYSE American, including
the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent director oversight
of the nomination of directors and executive compensation. In addition, we are not required, under the Exchange Act, to file current
reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered
under the Exchange Act and we are generally exempt from filing quarterly reports with the SEC. Also, although the Companies Law requires
us to disclose the annual compensation of our five most highly compensated directors and senior officers on an individual basis, this
disclosure is not as extensive as that required of a U.S. domestic issuer. For example, the disclosure required under Israeli law would
be limited to compensation paid in the immediately preceding year without any requirement to disclose option exercises and vested stock
options, pension benefits or potential payments upon